BL-1020 is a γ-aminobutyric acid (GABA)-enhanced antipsychotic that combines dopamine antagonism with GABA agonist activity. On the basis of animal models, we tested the hypotheses that BL-1020 would be effective in ameliorating both psychotic symptoms and cognitive impairments, with a favorable safety profile in acutely ill schizophrenia patients.

Geffen Y, Keefe R, Rabinowitz J, Anand R, Davidson, M. BL-1020, a new y-Aminobutyric acid-enhanced antipsychotic: Results of six-week, randomized, double-blind, controlled, efficacy and safety study. Journal of Clinical Psychiatry, 2012; 73(9) 1168-1174.